WOW !!! what a ride, shorts gotta cover, anybody who sold out will be chasing

This is what I dream of, big pharma's buying little Pharmas, now this article dates back to 2019, before the pandemic, but they do name all the big players and what they are looking for.


https://www.investors.com/news/technology/big-pharma-pharmaceutical-companies-mergers/

another company I'm invested in just upgraded their air condition and airflow threw out the facility, and lots of upgrades to the building.

Money is getting cheaper for the big guys and they are always on the lookout to improve their bottom line, almost everybody got hurt do to the pandemic,

jmop

Last year it was Aug 14, this year it should be Friday the 13th, the King will know the exact day, they changed from an accelerated filer

https://elite.irpass.com/Elite-Pharmaceuticals-Inc-Reports-Financial-Results-For-The-First-Quarter-Of-Fiscal-Year-2021-Ended-June-30-2020-And-Provides-Conference-Call-Information-8-14-2020

gonna miss ya Snup, stay close

I was reading the scroll at the bottom of the screen (Wallgreens down 7%) the only thing selling is generic Adderall for sure

Time for this one to come home.
Could be the competition wants to keep this one down, Hey, what's a million bucks to the likes of Teva, one less generic to compete with.

Don't stray to far Snup, one of these days we'LL need you back here,

STAY COOL

THX, looking good

Wow, 3 million shares, somebody wants this thing BAD

Found on yahoo, interesting

https://www.yahoo.com/news/fda-broken-controversial-approval-ineffective-120300323.html

some lite reading for the weekend, food for thought

Johnson & Johnson: Concerta and Risperdal
Johnson & Johnson's Concerta is also a stimulant. Concerta's main patents won't expire until 2017 and 2018, but generic versions have nonetheless been approved. After a court ruled that one of Concerta's patents was invalid in 2009, J&J reached agreements with Watson (now known as Actavis), Impax Laboratories, and other drugmakers to manufacture generic versions of the drug. Those generic versions have taken a bite out of J&J's pharmaceutical revenues.

Last quarter, Concerta sales fell 41% year over year to $150 million, due to competition from generic drugs. In 2013, sales fell 27% to $782 million -- a steep drop from the $1.3 billion in sales that it generated back in 2010.

That decline reduced Concerta from 5.9% of J&J's pharmaceutical revenue in 2010 to just 2.8% in 2013. However, J&J hasn't given up on protecting its remaining Concerta sales with more legal action. In 2013, it sued Osmotica Pharmaceutical's Hungarian Unit over generic Concerta, but later dropped the case. Earlier this month, it sued Mylan for the same reason.

Johnson & Johnson's involvement in the ADHD market doesn't end with Concerta, however. Its antipsychotic drug Risperdal has also been prescribed to children with ADHD in the past. That practice, along with several other controversial uses, led to a $2.2 billion fine for J&J last November for the improper off-label promotion of the drug to children and adults.

Alcobra: A newcomer in nonstimulant ADHD drugs
Last but not least, biotech Alcobra also works in this space. Alcobra's experimental drug Metadoxine Extended Release, or MDX, is a nonstimulant treatment being tested for predominantly inattentive ADHD, which accounts for 40% of all ADHD cases, and Fragile X syndrome, a genetic syndrome that causes autism in boys. MDX was shown to be effective and well tolerated in two phase 2 studies of adults with ADHD. It has begun enrolling patients in a phase 3 trial, with completion expected in the second half of this year.

Certainly, Alcobra is an interesting stock to watch. Nonetheless, this is a small, clinical-stage biotech, so an investment here is comparatively risky.

Foolish final thoughts
The market for ADHD treatments might initially appear saturated with generic drugs, such as cheaper versions of Shire's Adderall and J&J's Concerta.

However, Shire and Alcobra show us that there's still room for improvement in the market. Shire's Vyvanse shows that new formulations of stimulants can be less habit-forming than older ones, while demand for non-stimulants like Intuniv and Strattera remain high. That means there's still room for newcomers like Alcobra to find space in this market with newer nonstimulant treatments.

In conclusion, investors should keep a close eye on these companies and see which of their drugs benefit the most from the sharp rise in ADHD prescriptions over the past few years, especially if that growth continues.

Should you invest $1,000 in Johnson & Johnson right now?
Before you consider Johnson & Johnson, you'll want to hear this.

Our award-winning analyst team just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them.

The online investing service they've run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Express Scripts and Johnson & Johnson. The Motley Fool owns shares of Express Scripts and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

5 Stocks Under $49

We hear it over and over from investors, “I wish I had bought Amazon or Netflix when they were first recommended by the Motley Fool. I’d be sitting on a gold mine!” And it’s true.

And while Amazon and Netflix have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $49 a share!

You can grab a copy of “5 Growth Stocks Under $49” for FREE for a limited time only.

Click here to learn more.

Learn more

Motley Fool Returns
STOCK ADVISOR
S&P 500
593%
132%
Join Stock Advisor
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Stock Advisor launched in February of 2002. Returns as of 06/26/2021.

Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return
Motley Fools Stock Advisor has out performed the market by over 200% over the last 18 years
STOCKS
Johnson & Johnson Stock Quote
Johnson & Johnson
NYSE:JNJ
$164.21up$0.84(0.51%)
icon-one
Motley Fool Stock Advisor's Latest Pick

Get Access
593% Average Return

Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

RELATED ARTICLES

Darn, you own 900 million shares of this Pharma, you should own the company, and now you want a 100000 to one reverse split, smells fishy to me

Well, as I understood it, it was a 3 way split, plus extra for manufacturing fees, you will have to go the way back machine to see the details

I'm curious too, I mean, we all know you can't up list a 5 cent stock, minimum, 2 bucks, and that's with a lot of street Cred. however they do have every else in order. Cept the share price. Maybe he's talking about a deal with another company, that's my only guess right now.

THX

Just got email from seeking alpha, amended annual report , havent read yet

So let me dig a little deeper.

The revenues would have been even higher, but for a one-time inventory adjustment at our major sales and marketing partner had due to their financial situation.

Legal ees, Is it possible for Nasrat to sell to another distributor, say Prasco, for instance, the inventory that Lannett could not sell, due to the pandemic, there may be an OUT, after all, I would think Lannet wouldn't mind, given the circumstances. or are we trapped?

Of course, they will make it up to the Nasdaq, one of these days they will no longer need retail shares when they make their move.

Well, I'm all for it too, with the upgrades and that 1000 kilo fluid bed dryer, Nasrat said they can pump out up to 750 million pills a year, as long as they can get the API, maybe working 24 7, but it can be done.
my take is most of the plant sits idle, waiting for orders.

too bad Elite can't step up to the plate with a pill for covid

https://www.yahoo.com/news/pill-treat-covid-19-u-121338217.html?.tsrc=fp_deeplink

wheres LePree when we need him

Thanks for the shout out Snup, were all ok back on our ranch.

Thank you Snup, No bailing till November, maybe Nusrat will throw us a bone, this could get hot, as the pandemic eases and we get back to normal

Well, things change, IE pandemic, we will see if he makes a compromise,
we all see the numbers and potential. That generic plant in Jew jersey is state of the art, it's a clean machine.

Just a stumble, not a fall

Lannett would make a good bolt-on for JNJ

Can't wait till Jan. 22, or is it 22 fiscal which is now ?

OK, I'll bite, what are the 8 they are working on

What's up with Glenmark, I thought I heard a whisper years ago that Nasrat turned down their offer of a buyout, they wanted Elite for peanuts, as do others. and now we are back with Epic, I have no clue as to how Epic markets products


We have a new partner for Isradipine and Phentermine, which is actually an old partner, it’s Epic Pharma. These two products, Isradipine and Phentermine are interesting products because they have limited competition. Glenmark our previous partner was not able to give them the attention we believe they deserve. We expect Epic to be more effective in the marketing of these products.

What does this mean, did they reduce the order,?

Marc covered all the relevant financials. I just want to add that going from $7.5 million to $18 million to $25.4 million is a major achievement, even if we did not have once in a lifetime pandemic. The revenues would have been even higher, but for a one-time inventory adjustment at our major sales and marketing partner had due to their financial situation.

WOW TDA shows 1 mill on the bid,too, this is gonna take all-day, all they have to do is raise it a few ticks, they could get lost in the dust

looks like we got a wall at 6 cents even, pressure for sure

Put me down for 10 mill for the last Q. I lost the math for the year.

Just a thought, If big Pharmas are going to get hit with a 15% global tax, they might as well start buying up all the little guys first, before it kicks in, it's like monopoly money to the big boys, either that or pay out billions to Uncle Sam, or will it be the IMF, doesn't matter.

https://finance.yahoo.com/news/white-house-says-g7-leaders-214915227.html

I agree, Sctrben, one lost fact about up listing that is not being discussed

A company has four ways to get listed on the NASDAQ, depending on the underlying fundamentals of the company. Each company must have a minimum of 1,250,000 publicly traded shares outstanding upon listing, excluding those held by officers, directors, or any beneficial owners of more than 10% of the company.

My take on the increased share count, I voted for it, the company didn't want to borrow any more money from LC, and didn't want to do a reverse split, they needed to dilute to keep running, that's why I voted for it, to keep my shares intact. It's like a reverse split money-wise, now we are at 6 cents, we reversed our fortunes only to live another day.

Thanks for cleaning up the I box,

Monday monday, after hours, never saw that before,

Yep, it is sad, but if they want in they gotta ask, if it takes all day, we are all waiting till next week.

Just goes to show, no retail or insiders are sellen, not now, these are precious shares right now, held tightly

looks like somebody fishing, the bid and ask are like 2 or 3 micro points apart, if they want it they gotta pay, nobody is selling, for sure, this may take all day

TDA shows 700000 on the bid, WOW